Talk:Elexacaftor/tezacaftor/ivacaftor

This is the talk page for discussing improvements to the Elexacaftor/tezacaftor/ivacaftor article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Elexacaftor/tezacaftor/ivacaftor.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Wiki Education Foundation-supported course assignment

This article was the subject of a Wiki Education Foundation-supported course assignment, between 7 September 2021 and 13 December 2021. Further details are available on the course page. Student editor(s): Biomedjill.

Above undated message substituted from Template:Dashboard.wikiedu.org assignment by PrimeBOT (talk) 20:36, 17 January 2022 (UTC)[reply]

Merge proposal

Moving the stub, Elexacaftor, to here seems very reasonable. Best to consolidate closely-related material in one place. Klbrain (talk) 15:40, 10 February 2021 (UTC)[reply]

I find it awkward to have two or more drugboxes in one article. Also, I think it would be irritating to discuss one of the three components together with the combination, while the other two have their own articles. --ἀνυπόδητος (talk) 13:38, 18 February 2021 (UTC)[reply]

Fair enough; let's leave as-is; closing. Klbrain (talk) 07:23, 27 July 2021 (UTC)[reply]

Bibliography for updates

Middleton, Peter G.; Mall, Marcus A.; Dřevínek, Pavel; Lands, Larry C.; McKone, Edward F.; Polineni, Deepika; Ramsey, Bonnie W.; Taylor-Cousar, Jennifer L.; Tullis, Elizabeth; Vermeulen, François; Marigowda, Gautham (2019-11-07). "Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele". New England Journal of Medicine. 381 (19): 1809–1819. doi:10.1056/NEJMoa1908639. ISSN 0028-4793. PMC 7282384. PMID 31697873.
Middleton PG, Mall MA, Dřevínek P, et al. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381(19):1809-1819. doi:10.1056/NEJMoa1908639
Zemanick ET, Taylor-Cousar JL, Davies J, et al. A phase 3 open-label study of ELX/TEZ/IVA in children 6 through 11 years of age with CF and at least one F508del allele. Am J Respir Crit Care Med. 2021;203(12):1522-1532. doi: 10.1164/rccm.202102-0509OC
Zaher A, Elsaygh J, Elsori D, et al. (July 03, 2021) A Review of Trikafta: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy. Cureus 13(7): e16144. doi:10.7759/cureus.16144
PhD, Ines Martins. "Trikafta Very Effective CF Therapy, But Still Too Costly, ICER Reports". Retrieved August 21, 2020.
"Modulator Treatments for Cystic Fibrosis: Effectiveness and Value" (PDF). Institute for Clinical and Economic Review. Institute for Clinical and Economic Review. April 27, 2020. Retrieved August 21, 2020.
Bethesda, Cystic Fibrosis Foundation 4550 Montgomery Ave Suite 1100 N.; Md 20814301-951-4422 800-344-4823. "FDA Approves Expansion of Modulators for People With Certain Rare Mutations". www.cff.org. Retrieved 2021-10-03.
Bethesda, Cystic Fibrosis Foundation 4550 Montgomery Ave Suite 1100 N.; Md 20814301-951-4422 800-344-4823. "FDA Accepts Vertex Application for Expansion of Trikafta to Include Children ages 6-11". www.cff.org. Retrieved 2021-10-03.
"Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Retrieved 2021-10-17.
Vertex Pharmaceuticals. Trikafta (Elexacaftor/tezacaftor/ivacaftor) [package insert]. U.S. Food and Drug Administration website.https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212273s004lbl.pdf. Revised June 2021. Accessed October 3, 2021.
Vertex Pharmaceuticals. Trikafta (Elexacaftor/tezacaftor/ivacaftor) [clinical brochure] https://www.trikaftahcp.com/sites/default/files/clinical-brochure.pdf
"Trikafta Side Effects". Drugs.com. January 24, 2021. Retrieved October 3, 2021.
"elexacaftor/tezacaftor/ivacaftor (Rx)". Medscape. Retrieved October 3, 2021. — Preceding unsigned comment added by Biomedjill (talk • contribs) 18:56, 17 October 2021 (UTC)[reply]

Biomedjill (talk) 19:13, 17 October 2021 (UTC)[reply]

text formatting issue

In the table at http://en.wiki.x.io/wiki/Elexacaftor/tezacaftor/ivacaftor#Research there is a formatting issue (CSS? font-family? text-align?) in the cell on row "trial 3" and column "Target mutations", which is more obvious if you try to print the article onto paper — or save it as PDF. 2001:6B0:E:2B18:0:0:0:72 (talk) 17:31, 19 November 2022 (UTC)[reply]

NY Times article on the unavailability of Trikafta globally

Article here: [1]. Thriley (talk) 05:53, 8 February 2023 (UTC)[reply]

Mental side effects

Study here: [2]. Thriley (talk) 03:05, 13 February 2023 (UTC)[reply]

Weight gain and hypertension

Study here [3] ~dom Kaos~ (talk) 13:19, 12 June 2023 (UTC)[reply]

Merge figures

Would it make sense to merge the three figures for each of the components? I've seen other articles regarding combination drugs doing this. I wouldn't know how to do it myself. 82.147.226.240 (talk) 13:35, 6 October 2023 (UTC)[reply]